Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.67 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.67 |
| ▸ | MAOA | P21397 | 5/20 | 0.64 |
| ▸ | MAOB | P27338 | 5/20 | 0.64 |
| ▸ | HTR6 | P50406 | 5/20 | 0.61 |
| ▸ | HRH1 | P35367 | 4/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15536553 | 0.86 | HTR6 (0.69) | SIRT2SIRT1MAOAMAOBHTR6 | |
| SCHEMBL15547688 | 0.82 | SIRT2 (0.58) | SIRT2SIRT1MAOAMAOBHTR6 | |
| SCHEMBL15132703 | 0.81 | MAOA (0.60) | SIRT2SIRT1MAOAMAOBHTR6 | |
| SCHEMBL16968504 | 0.80 | SIRT2 (1.00) | SIRT2SIRT1MAOAMAOBHTR6 | |
| SCHEMBL15550724 | 0.80 | SIRT2 (0.67) | SIRT2SIRT1MAOAMAOB | |
| SCHEMBL13696055 | 0.80 | HTR6 (0.77) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL16978496 | 0.79 | SIRT2 (1.00) | SIRT2SIRT1MAOAMAOBHTR6 | |
| SCHEMBL13696064 | 0.78 | HTR6 (0.67) | HTR6HRH1HDAC1HDAC6ADRA2A | |
| SCHEMBL3339737 | 0.77 | SIGMAR1 (0.54) | — | |
| SCHEMBL3823482 | 0.77 | SIGMAR1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422238-B2 | ICMT inhibitors | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-20150218095-A1 | ICMT INHIBITORS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2015-08-06 | — | — | US | disclosed |
| WO-2013180656-A1 | ICMT Inhibitors | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218095-A1 | ICMT INHIBITORS | INMT, CEPT1, ICMT | SIRT2 1263/4885SIRT1 2389/4885MAOA 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.